Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate

Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate is a phase 2, randomised interventional study registered as NCT07230509 by Minia University, with a registry enrolment figure of 90 participants, started 2025-12-01 and due to reach its primary completion in 2027-12-01. Interventions recorded: Pancreatic parenchymal injection of N-butyl-2- cyanoacrylate(Histoacryl®)Injection Group.; Standard Pancreaticojejunostomy. Conditions listed: Pancreaticoduodenectomy; Postoperative Pancreatic Fistula; Pancreas Cancer; Periampullary Cancer. Primary outcome: Incidence of postoperative pancreatic fistula. Pancreatic eligibility wording from the registry: "* Patients undergoing pancreaticoduodenectomy for malignant lesions meeting the curative treatment intent in accordance with clinical guidelines". Sites: Egypt. No results are recorded here; the registry entry is the source.